Yeah completely agree MSA needs to be the main focus until we know yes/no for AA, and I don't think we need to worry about Stamler and co straying from that. But with the injection of cash it should allow some resources to other lines of research. If AA comes through then cash shouldn't be such an issue anymore and we could have a few more directions to explore -
Parkinson's ph2 for 434
Friedrich's Ataxia ph2a for 434
Ph2a PBT2 antibiotic resistant infection (assuming ph1 from previous AD & HD work could be used..)
And perhaps a new molecule, or 434, in Alzheimer's disease, like the company has been hinting to
Maybe also 434 in Dementia with Lewy Bodies ph2a
Of course these on top of a confirmatory ph 3 in MSA is a huge cost so the company would need to valued a lot higher, but that could happen if AA comes through IMO.
Also continuing on the PBT2 research, I've tried to answer my own question. December 2020 is last PBT2 ASX announcement ATH made on PBT2 from my searching and reads quite good in that PBT2 is patent protected for combating antibiotic resistance superbugs until 2038, with Alterity securing the worldwide exclusive licence by licencing PBT2 from Uniquest. Uniquest will receive milestone and royalty payments from ATH once any revenue comes in. Not sure if Doherty Institute get a slice also, or perhaps they have agreement with Uniquest.
https://app.sharelinktechnologies.com/announcement/asx/0a5f8757d430e5de09bf67726cb9bcdfAlso I found this in 2024 annual report regarding PBT2 in AD, cheers. In March 2023, we announced a sub-licensing agreement for PBT2 to Professor Colin Masters, M.D., A.O., to advance compounds for the treatment of Alzheimer’s and related diseases. Under the license agreement, Alterity grants the entire rights to the acyl hydrazone patent mentioned above, as well as an exclusive worldwide license to develop and commercialize both acyl hydrazone and PBT2 in Alzheimer’s disease. In exchange, Alterity is entitled to future royalties of net sales from the assets.
,
ATH Price at posting:
1.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)